Published in Thromb Haemost on November 01, 2001
Thrombotic, Inflammatory & Gene Markers of CVD in Women | NCT00006539
Inflammation, Infection, and Future Cardiovascular Risk | NCT00005496
Associations between interleukin-1 gene polymorphisms and coronary heart disease risk: a meta-analysis. PLoS One (2012) 0.82
Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Med Genet (2004) 0.81
Genetics of coronary heart disease with reference to ApoAI-CIII-AIV gene region. World J Cardiol (2014) 0.79
Genetic polymorphisms to evaluate the risk of myocardial infarction: a long way away. Thromb Haemost (2001) 0.76
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell (1991) 9.99
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet (1997) 4.27
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet (2002) 4.00
Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation (1998) 3.89
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med (1995) 3.88
Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. Nature (1991) 3.74
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem (2001) 2.67
The primary prevention of myocardial infarction. N Engl J Med (1992) 2.63
Blood pressure and inflammation in apparently healthy men. Hypertension (2001) 2.55
Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation (2001) 2.54
Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol (2001) 2.50
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med (1995) 2.31
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J (2001) 2.12
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol (2001) 2.11
Incremental reductions of positive charge within the S4 region of a voltage-gated K+ channel result in corresponding decreases in gating charge. Neuron (1992) 2.09
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem (2001) 2.06
Selecting SNPs in two-stage analysis of disease association data: a model-free approach. Ann Hum Genet (2000) 2.05
Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum. J Mol Med (Berl) (2000) 2.04
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia (2007) 2.03
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat Genet (1996) 1.98
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med (1992) 1.92
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation (1997) 1.63
Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol (2000) 1.62
Height and incidence of cardiovascular disease in male physicians. Circulation (1993) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost (2006) 1.61
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation (1999) 1.57
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol (1999) 1.54
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Why map the rat? Trends Genet (1997) 1.51
Surgical management of carcinoid heart disease. Ann Thorac Surg (1991) 1.50
C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. J Thromb Haemost (2004) 1.46
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J (2002) 1.45
Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun (2006) 1.44
Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol (2001) 1.44
Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J (2001) 1.44
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol (1995) 1.44
A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure. J Mol Med (Berl) (2000) 1.39
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? JAMA (1996) 1.39
Factor V Leiden and recurrent venous thromboembolism. Thromb Haemost (1996) 1.39
A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol (2001) 1.38
Caveat emptor. Hypertension (1994) 1.36
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol (1999) 1.33
Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol (1998) 1.32
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation (1998) 1.31
Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med (2001) 1.30
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med (1990) 1.25
Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation (1995) 1.24
Lipid levels and the risk of ischemic stroke in women. Neurology (2007) 1.23
Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med (2007) 1.22
Gating charge differences between two voltage-gated K+ channels are due to the specific charge content of their respective S4 regions. Neuron (1993) 1.22
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Mapping of both autosomal recessive and dominant variants of pseudoxanthoma elasticum to chromosome 16p13.1. Hum Mol Genet (1997) 1.21
Migraine and biomarkers of cardiovascular disease in women. Cephalalgia (2007) 1.21
Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet (2006) 1.14
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med (1997) 1.13
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation (2000) 1.13
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation (1997) 1.11
Tissue- and development-specific expression of multiple alternatively spliced transcripts of rat neuronal nitric oxide synthase. J Clin Invest (1997) 1.10
Innovative newborn health technology for resource-limited environments. Trop Med Int Health (2013) 1.10
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation (1997) 1.08
A linkage map of the rat genome derived from three F2 crosses. Genome Res (1997) 1.08
C-reactive protein, inflammation, and coronary risk. Med Clin North Am (2000) 1.06
Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol (1999) 1.06
Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J Thromb Haemost (2009) 1.05
Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing. Circ Res (1999) 1.05
Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol (2000) 1.05
A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis (2001) 1.03
Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation (1997) 1.02
The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation (1999) 1.01
Quantitative trait loci in genetically hypertensive rats. Possible sex specificity. Hypertension (1996) 1.01
Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol (1999) 1.01
Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology (1985) 0.99
Pseudoxanthoma elasticum: evaluation of diagnostic criteria based on molecular data. Br J Dermatol (2006) 0.98
Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J Thromb Haemost (2006) 0.97
Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation (1997) 0.96
Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet (2006) 0.95
The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep (1999) 0.94
A novel Q378X mutation exists in the transmembrane transporter protein ABCC6 and its pseudogene: implications for mutation analysis in pseudoxanthoma elasticum. J Mol Med (Berl) (2001) 0.93